BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015;35:562-568. [PMID: 24351080 DOI: 10.1111/liv.12442] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Engstler AJ, Sellmann C, Jin CJ, Brandt A, Herz K, Priebs J, Bergheim I. Treatment with alpha-galactosylceramide protects mice from early onset of nonalcoholic steatohepatitis: Role of intestinal barrier function. Mol Nutr Food Res 2017;61. [PMID: 28067024 DOI: 10.1002/mnfr.201600985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
2 Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol 2019;234:8286-94. [PMID: 30417367 DOI: 10.1002/jcp.27699] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
3 Chi ZC. Pathogenesis of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 670-683 [DOI: 10.11569/wcjd.v25.i8.670] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Gangarapu V, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015;27:840-5. [PMID: 26043290 DOI: 10.1097/MEG.0000000000000348] [Cited by in Crossref: 72] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
5 Assante G, Williams R, Youngson NA. Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? J Hepatol 2021;74:487-8. [PMID: 32574578 DOI: 10.1016/j.jhep.2020.05.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Nier A, Brandt A, Conzelmann IB, Özel Y, Bergheim I. Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern. Nutrients 2018;10:E1329. [PMID: 30235828 DOI: 10.3390/nu10091329] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
7 Nier A, Brandt A, Rajcic D, Bruns T, Bergheim I. Short-Term Isocaloric Intake of a Fructose- but not Glucose-Rich Diet Affects Bacterial Endotoxin Concentrations and Markers of Metabolic Health in Normal Weight Healthy Subjects. Mol Nutr Food Res 2019;63:e1800868. [PMID: 30570214 DOI: 10.1002/mnfr.201800868] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Dai C, Yang L, Jin J, Wang H, Wu S, Bao W. Regulation and Molecular Mechanism of TLR5 on Resistance to Escherichia coli F18 in Weaned Piglets. Animals (Basel) 2019;9:E735. [PMID: 31569693 DOI: 10.3390/ani9100735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15:e27909. [PMID: 26045709 DOI: 10.5812/hepatmon.15(5)2015.27909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bergheim I, Schuppan D. Microbiome and Diseases: Hepatic Disorders. In: Haller D, editor. The Gut Microbiome in Health and Disease. Cham: Springer International Publishing; 2018. pp. 279-93. [DOI: 10.1007/978-3-319-90545-7_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Rajcic D, Baumann A, Hernández-Arriaga A, Brandt A, Nier A, Jin CJ, Sánchez V, Jung F, Camarinha-Silva A, Bergheim I. Citrulline supplementation attenuates the development of non-alcoholic steatohepatitis in female mice through mechanisms involving intestinal arginase. Redox Biol 2021;41:101879. [PMID: 33550112 DOI: 10.1016/j.redox.2021.101879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jin CJ, Engstler AJ, Ziegenhardt D, Bischoff SC, Trautwein C, Bergheim I. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease (NAFLD) in mice. J Gastroenterol Hepatol. 2016; Epub ahead of print. [PMID: 27404046 DOI: 10.1111/jgh.13488] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
13 Engstler AJ, Aumiller T, Degen C, Dürr M, Weiss E, Maier IB, Schattenberg JM, Jin CJ, Sellmann C, Bergheim I. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut 2016;65:1564-71. [PMID: 26006114 DOI: 10.1136/gutjnl-2014-308379] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
14 Eliades M, Spyrou E. Vitamin D: A new player in non-alcoholic fatty liver disease? World J Gastroenterol 2015; 21(6): 1718-1727 [PMID: 25684936 DOI: 10.3748/wjg.v21.i6.1718] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 71] [Article Influence: 11.7] [Reference Citation Analysis]
15 Podszun MC, Chung JY, Ylaya K, Kleiner DE, Hewitt SM, Rotman Y. 4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. J Histochem Cytochem 2020;68:635-43. [PMID: 32867573 DOI: 10.1369/0022155420946402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
16 Patusco R, Smith TJ, Ziegler J. The Role of Fructose, and Specifically Sugar-Sweetened Beverages, in Pediatric Nonalcoholic Fatty Liver Disease. Topics in Clinical Nutrition 2017;32:27-46. [DOI: 10.1097/tin.0000000000000091] [Reference Citation Analysis]
17 Aragonès G, Colom-Pellicer M, Aguilar C, Guiu-Jurado E, Martínez S, Sabench F, Antonio Porras J, Riesco D, Del Castillo D, Richart C, Auguet T. Circulating microbiota-derived metabolites: a "liquid biopsy? Int J Obes (Lond) 2020;44:875-85. [PMID: 31388096 DOI: 10.1038/s41366-019-0430-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
18 Ajith TA. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2018;45:413-421. [PMID: 29112771 DOI: 10.1111/1440-1681.12886] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
19 Engstler AJ, Frahnow T, Kruse M, Pfeiffer AFH, Bergheim I. Plasminogen Activator Inhibitor-1 is Regulated Through Dietary Fat Intake and Heritability: Studies in Twins. Twin Res Hum Genet 2017;20:338-48. [DOI: 10.1017/thg.2017.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Sellmann C, Jin CJ, Degen C, De Bandt J, Bergheim I. Oral Glutamine Supplementation Protects Female Mice from Nonalcoholic Steatohepatitis. The Journal of Nutrition 2015;145:2280-6. [DOI: 10.3945/jn.115.215517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
21 Munukka E, Wiklund P, Partanen T, Välimäki S, Laakkonen EK, Lehti M, Fischer-Posovzsky P, Wabitsch M, Cheng S, Huovinen P, Pekkala S. Adipocytes as a Link Between Gut Microbiota-Derived Flagellin and Hepatocyte Fat Accumulation. PLoS One 2016;11:e0152786. [PMID: 27035341 DOI: 10.1371/journal.pone.0152786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
22 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
23 Qu BG. Inflammatory and immune changes and treatment in patients with fatty liver disease. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2931-2942 [DOI: 10.11569/wcjd.v24.i19.2931] [Reference Citation Analysis]
24 Kim S, Park S, Kim B, Kwon J. Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease. Sci Rep. 2016;6:27849. [PMID: 27279075 DOI: 10.1038/srep27849] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
25 Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(8): 570-579 [PMID: 25232450 DOI: 10.4254/wjh.v6.i8.570] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.9] [Reference Citation Analysis]
26 Jin CJ, Sellmann C, Engstler AJ, Ziegenhardt D, Bergheim I. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). Br J Nutr. 2015;114:1745-1755. [PMID: 26450277 DOI: 10.1017/s0007114515003621] [Cited by in Crossref: 55] [Cited by in F6Publishing: 33] [Article Influence: 7.9] [Reference Citation Analysis]
27 Podszun MC, Frank J. Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease. Redox Biol 2021;42:101937. [PMID: 33773953 DOI: 10.1016/j.redox.2021.101937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Jin CJ, Engstler AJ, Sellmann C, Ziegenhardt D, Landmann M, Kanuri G, Lounis H, Schröder M, Vetter W, Bergheim I. Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation. Br J Nutr 2016;116:1682-93. [DOI: 10.1017/s0007114516004025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
29 Sellmann C, Jin CJ, Engstler AJ, De Bandt JP, Bergheim I. Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD). Eur J Nutr 2017;56:2519-27. [PMID: 27496089 DOI: 10.1007/s00394-016-1287-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
30 Baumann A, Jin CJ, Brandt A, Sellmann C, Nier A, Burkard M, Venturelli S, Bergheim I. Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis. Nutrients 2020;12:E951. [PMID: 32235497 DOI: 10.3390/nu12040951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
31 Baumann A, Nier A, Hernández-Arriaga A, Brandt A, Lorenzo Pisarello MJ, Jin CJ, Pilar E, Camarinha-Silva A, Schattenberg JM, Bergheim I. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Sci Rep 2021;11:17815. [PMID: 34497333 DOI: 10.1038/s41598-021-97346-9] [Reference Citation Analysis]
32 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30:1190-1196. [PMID: 25684563 DOI: 10.1111/jgh.12924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]